HER3-DXd May Lead to an Additional Treatment Option in EGFR+ NSCLC
Cancer Network,
Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA…
Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA…
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple…
“The promising results from the MARIPOSA-2 study show that by combining [amivantamab] with chemotherapy, both with and without…
This submission is supported by data from the Phase 3 MARIPOSA-2 Study featured in a Late-Breaking Presidential Symposium…